Stockscreener 앱 받기
9.85
5.01%
0.47
시간 외 거래:
9.99
0.14
+1.42%
전일 마감가:
$9.38
열려 있는:
$9.49
하루 거래량:
849.13K
Relative Volume:
0.69
시가총액:
$828.59M
수익:
순이익/손실:
$-44.17M
주가수익비율:
-18.73
EPS:
-0.526
순현금흐름:
$-35.14M
1주 성능:
-3.53%
1개월 성능:
-23.94%
6개월 성능:
-34.81%
1년 성능:
+28.09%
1일 변동 폭
$9.36
$10.07
1주일 범위
$9.21
$10.71
52주 변동 폭
$6.39
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
9.85 | 828.59M | 0 | -44.17M | -35.14M | -0.526 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Goldman | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus Pharma Q2 2026 Earnings Call Transcript - Benzinga
Other investing cash flow items (total) of Corvus Pharmaceuticals, Inc. – FWB:C17 - TradingView
Corvus Pharmaceuticals Inc. R (C17.HA) analyst ratings, estimates and forecasts - Yahoo Finance UK
Corvus Pharma Com (CRVS-Q) Stock Price and News - The Globe and Mail
Corvus Pharmaceuticals Announces Initiation of Phase 1b - GlobeNewswire
One drug is now in trials for four conditions, including a skin disease. - stocktitan.net
Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa - Yahoo! Finance Canada
Corvus Pharmaceuticals,Primary Endpoint Is - Moomoo
Enterprise value of Corvus Pharmaceuticals, Inc. – HAN:C17 - TradingView
Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In? - Yahoo! Finance Canada
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com India
Corvus Pharmaceuticals at cantor global healthcare: pipeline bets widen By Investing.com - Investing.com Canada
Trial Results Published Could Be A Game Changer For Corvus Pharmaceuticals (CRVS) - simplywall.st
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference - marketscreener.com
A biotech company's live healthcare talk is set for Sept. 10. Its webcast stays online 90 days. - Stock Titan
Corvus Pharmaceuticals Inc. (CRVS) Peer Comparison – Compare with Others - valueresearchonline.com
Corvus Pharmaceuticals (CRVS) Declines 3.8% to $14.16 as Stock Tests Key Support at $13.45NHNL Divergence - vinanet.vn
Corvus Pharmaceuticals (CRVS) Declines 3.8% to $14.16 as Stock Tests Key Support at $13.45Put Call Ratio - dars.gov.et
Corvus Pharmaceuticals Publishes Blood Data Showing Soquelitinib Activity in T Cell Lymphoma and Supporting Ongoing PTCL, Atopic Dermatitis Trials - quiverquant.com
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment - Seeking Alpha
Corvus Pharmaceuticals Publishes Blood Data Showing Soquelitinib Activity in T Cell Lymphoma and Supporting Ongoing PTCL, Atopic Dermatitis Trials - Quiver Quantitative
Corvus lymphoma study: 67% were alive at 24 months after 1-3 prior therapies - stocktitan.net
Corvus Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRVS - TradingView
Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st
637,500 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by DCF Advisers LLC - MarketBeat
Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current UpdateFinancial Health Score - vinanet.vn
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - finance.yahoo.com
Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap? - Sahm
Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us
Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha
HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat
The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha
Corvus Pharmaceuticals (CRVS) Pulls Back 3% as Biotech Volatility PersistsOvervalued Signals - vinanet.vn
Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Corvus Pharmaceuticals Inc 주식 (CRVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 18 '26 |
Buy |
12.04 |
6,932 |
83,453 |
1,195,035 |
| Thompson Peter A. | Director |
Jan 28 '26 |
Option Exercise |
5.33 |
210,000 |
1,119,374 |
210,000 |
3.40%
자본화:
|
볼륨(24시간):